image description

Tag: itolizumab

LRA Congratulates Equillium on Positive Results of Study of Potential New Lupus Treatment

March 30, 2021 Equillium, Inc. announced positive topline data from the phase 1b EQUALISE study in patients with systemic lupus erythematosus (SLE).  This study suggests that itolizumab, a monoclonal antibody selectively targeting the CD6-ALCAM pathway, was safe and well tolerated among people with SLE. [Source: Equillium, Inc. Press Release 3.30.21] The EQUALISE study is evaluating […] Read More

LRA Shares Excitement For What’s Ahead in Lupus Nephritis

January 16, 2020 Up to half of people with lupus will have lupus nephritis – damage to the kidneys that affects the ability to clear the body of wastes and toxins. In 2020, we expect to see significant progress in new drug development for lupus and lupus nephritis in particular with submissions for FDA approval in […] Read More

LRA Celebrates Major Research Breakthroughs in 2019

January 7, 2020 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago. The past 12 months delivered many […] Read More

Great News for Lupus Nephritis Treatment: Itolizumab Fast-Tracked by FDA

December 10, 2019 The Lupus Research Alliance (LRA) is pleased to share that a potential new treatment in development by Equillium, Inc. for lupus nephritis, itolizumab, was granted Fast Track designation by the U.S. Food and Drug Administration.  As defined by the FDA, this designation is “designed to facilitate the development, and expedite the review […] Read More

LRA Applauds Exciting Lupus Research Being Presented at 2019 ACR/ARP Annual Meeting

Includes 16 presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from two clinical studies conducted by LRA-affiliate Lupus Therapeutics (LT) in collaboration with Rilite Foundation and Pfizer to be presented Extensive positive studies focused on lupus, including successful Phase 3 and Phase 2 clinical and mechanistic data […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates